BioTuesdays

Capricor prices common stock offering

Capricor Therapeutics (NASDAQ:CAPR) has priced a public offering of 4,412,000 common shares at a price of $17.00 per share. Capricor also granted underwriters a 30-day option to purchase up to an additional 661,800...

BTIG starts Definitive Healthcare at buy; PT $7

BTIG launched coverage of Definitive Healthcare (NASDAQ:DH) with a “buy” rating and $7 target price. The stock closed at $4.44 on September 16. Definitive Healthcare is one of the industry’s most comprehensive...

EF Hutton starts CytoSorbents at buy; PT $10

EF Hutton launched coverage of CytoSorbents (NASDAQ:CTSO) with a “buy” rating and $10 target price. The stock closed at $1.03 on July 26. CytoSorbents’ innovative filter cartridges, CytoSorb, and DrugSorb, stand...

Profound Medical

Lake Street starts Profound Medical at Buy; PT $16.50

Lake Street initiated coverage of Profound Medical (NASDAQ:PROF; TSX:PRN) with a “buy” rating and $16.50 price target. The stock closed at $10.19 on July 22. Analyst Ben Haynor writes that with reimbursement of TULSA...

EF Hutton starts Citius Pharmaceuticals at buy; PT $6

EF Hutton launched coverage of Citius Pharmaceuticals (NASDAQ:CTXR) a “buy” rating and $6 target price. The stock closed at $0.7340 on July 12. Citius is a pharmaceutical/biotechnology company with two late-stage assets...

William Blair starts Solid Biosciences at OP

William Blair launched coverage of Solid Biosciences (NASDAQ:SLDB) with an “outperform” rating. The stock closed at $14.25 on March 27. Solid Biosciences is a development-stage biotechnology company transitioning to...

Gracell Biotechnologies

Evercore starts Gracell Biotech at OP

Evercore ISI initiated coverage of Gracell Biotechnologies (NASDAQ:GRCL) with an “outperform” rating and no price target. The stock was quoted at $5.43 midday on Nov. 27. Gracell is developing a unique CAR-T construct...

Annovis Logo

Brookline starts Annovis Bio at buy; PT $35

Brookline Capital Markets initiated coverage of Annovis Bio (NASDAQ:ANVS) with a “buy” rating and price target of $35. The stock was quoted at $5.85 midday on Nov. 10. Annovis is developing treatments for...

Myomo

AGP ups Myomo to buy; PT $4.60 from $2

Alliance Global Partners upgraded Myomo (NYSE:MYO) to “buy” and raised its price target to $4.60 from $2. The stock was quoted at $1.85 midday on Nov.8. Myomo develops and markets the MyoPro product line of lightweight...

Adlai-Nortye-Logo

Cantor starts Adlai Nortye at OW; PT $30

Cantor Fitzgerald launched coverage of Adlai Nortye (NASDAQ:ANL) with an “overweight” rating and price target of $30. The stock closed at $8.52 on Oct 24. The company is focused on the discovery and development of...

JMP starts Vigil Neuroscience at MO; PT $23

JMP Securities initiated coverage of Vigil Neuroscience (NASDAQ:VIGL) with a “market outperform” rating and price target of $23. The stock was quoted at $6.50 midday on Oct 18. Vigil is developing novel therapies for...

Spheric BioCantor starts Solid at OW; PT $5

Cantor Fitzgerald launched coverage of Solid Biosciences (NASDAQ:SLDB) with an “overweight” rating and 12-month price target of $5. The stock closed at $2.76 on Sept. 22. Solid is using its gene therapy platform to...

Profound Medical

RJ ups Profound Medical to strong buy

Raymond James upgraded Profound Medical (NASDAQ:PROF; TSX:PRN) to “strong buy” from “outperform” with a price target of $20.00, after pricing-in the TULSA-PRO system’s 2025 sales inflection. At mid-day on September 18...

Nanox-Imaging-Logo

AGP starts Nano-X Imaging at buy; PT $14.50

Alliance Global Partners initiated coverage of Nano-X Imaging (NASDAQ:NNOX) with a “buy” rating and price target of $14.50. The stock closed at $7.66 on Sept. 7. “Nano-X’s novel digital X-ray source has the potential to...